WASHINGTON, D.C. — In a landmark shift in federal health policy, the Centers for Medicare & Medicaid Services (CMS) launched the Medicare GLP-1 Bridge program on July 1, 2026, granting eligible Medicare beneficiaries access to groundbreaking weight-loss medications for just $50 per month.

The time-limited demonstration program, which runs through December 31, 2027, represents the first time Medicare will cover GLP-1 medications specifically for obesity treatment, circumventing a decades-old federal prohibition that previously barred coverage of weight-loss drugs alone.

The program covers GLP-1 receptor agonists from pharmaceutical giants Novo Nordisk and Eli Lilly, including Wegovy (both injection and pill formulations), Zepbound KwikPen, and the newly launched Foundayo daily tablet.

Eligibility Requirements: Who Qualifies?

To qualify for the program, Medicare Part D enrollees must meet specific clinical criteria based on body mass index (BMI) and comorbidities:

• BMI of 35 or higher (no additional conditions required)
• BMI of 30 or higher plus history of heart failure, uncontrolled hypertension, or chronic kidney disease
• BMI of 27 or higher plus prediabetes, previous heart attack or stroke, or symptomatic peripheral artery disease

According to KFF estimates, approximately 3.8 million Medicare beneficiaries meet these eligibility requirements, though pharmaceutical companies Novo Nordisk and Eli Lilly suggest the potential patient pool could reach 15 to 20 million older adults.

How the Program Works

Unlike traditional Medicare Part D coverage, the Bridge program operates through a centralized prior authorization system administered by Humana. Healthcare providers must submit documentation certifying that patients meet clinical eligibility criteria, with CMS expecting approvals within 72 hours of electronic submission.

Once approved, patients pay the flat $50 copayment directly at the pharmacy when picking up their prescription, regardless of dosage strength.

Industry Implications and Market Impact

The program marks a watershed moment for Novo Nordisk and Eli Lilly, unlocking a vast new patient population. Lilly currently leads with approximately 60% market share compared to Novo's 39% as of Q1 2026.

Analysts at Leerink Partners project the program could generate more than $1 billion in annual revenue for each company, with oral formulations particularly appealing to seniors—Novo's market research indicates 75% of older adults prefer daily pills over weekly injections.

The Path Forward

CMS originally envisioned Bridge as a six-month transition to a longer-term program called Balance, which would shift coverage responsibility to private Part D insurers. However, major insurers including CVS and UnitedHealthcare declined to participate voluntarily, citing concerns about program structure and costs.

A permanent solution would require Congressional passage of the Treat and Reduce Obesity Act, which would lift Medicare's statutory ban on obesity drug coverage. Despite bipartisan support, the legislation faces impediments due to cost concerns—the Congressional Budget Office estimated a $35 billion federal spending increase over nine years, though supporters argue this overstates net costs by not fully capturing potential savings from preventing obesity-related conditions.

As the program launches, CMS officials emphasized they will "carefully track participation and outcomes" to inform future policy decisions, with Dr. Holly Lofton, director of the Medical Weight Management Program at NYU Langone, calling the initiative a transformative step that will "improve access to so many Americans who need these medications."